The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
UNAIDS | 2016–2021 Strategy
Accessed: 20.11.2019
Overwhelming evidence shows that a range of health concerns—mental illness, substance dependence, HIV/AIDS, and noncommunicable diseases—affect prisoners disproportionately. But, while incarceration poses risks to health—including inadequate nutrition and exposure to violence—prisons also pr...esent important opportunities to promote health and risk reduction that need to be tapped.
Some recommended remedies:
Health ministries, not ministries of justice, should manage health care responsibilities
Ensure that testing is available, but not mandatory, for infectious diseases
Make prison health part of the broader public health agenda
more
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0189770 January 2, 2018
Accelerating HIV prevention to reduce new infections by 75%
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more
African Evaluation Journal
ISSN: (Online) 2306-5133, (Print) 2310-4988
Background: For some years, non-governmental organisations (NGOs) and civil society have
become increasingly involved in the fight against the HIV/AIDS pandemic in Africa. But even
though their role is well appreciated, the...ir actions are perceived as ineffective because of a lack
of monitoring and evaluation capacity.
Objective: This paper aims to describe local HIV/AIDS NGOs’ involvement in evaluation and
the characteristics of this involvement.
more
Strengthening the capacities of SUN Countries by sharing and disseminating good practices in the fight against malnutrition.
This report is a summary of the results of the preparation and implementation of the Learning Route (LR) organized jointly by the SUN (Scaling Up Nutrition) Movement’s S...ecretariat, the Fight Against Malnutrition Unit (CLM, Cellule de Lutte contre la Malnutrition) and PROCASUR Corporation; this Learning Route was held in Senegal from the 26th of May to the 1st of June, 2014. The aim of this publication is to illustrate the experience, its main outcomes, and the lessons learned.
more
UNAIDS Joint United Nations Programme on HIV/AIDS
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...see: it is estimated that each year, drug-resistant infections result in at least 25 000 patient deaths and cost the EU EUR 1,5 billion in healthcare costs and through loss of productivity
more
Choko AT et al. Journal of the International AIDS Society 2017, 20:21610 http://www.jiasociety.org/index.php/jias/article/view/21610 | http://dx.doi.org/10.7448/IAS.20.1.21610
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac...hed a tipping point where large and prominent drugmakers have retreated from the antibiotics field and smaller innovative biotech companies have gone bankrupt due to the poor financial rewards on offer.
more